🚀 VC round data is live in beta, check it out!
Genetic Analysis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Genetic Analysis and similar public comparables like Prostatype Genomics, Brainscan, Elite Diagnostic, Spermosens and more.
Genetic Analysis Overview
About Genetic Analysis
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world.
Founded
2008
HQ
Employees
16
Website
Financials (LTM)
EV
$4M
Genetic Analysis Financials
Genetic Analysis reported last 12-month revenue of $2M and negative EBITDA of ($592K).
In the same LTM period, Genetic Analysis generated $1M in gross profit, ($592K) in EBITDA losses, and had net loss of ($1M).
Revenue (LTM)
Genetic Analysis P&L
In the most recent fiscal year, Genetic Analysis reported revenue of $2M and EBITDA of ($592K).
Genetic Analysis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $1M | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | ($592K) | XXX | ($592K) | XXX | XXX | XXX |
| EBITDA Margin | (31%) | XXX | (34%) | XXX | XXX | XXX |
| EBIT Margin | (59%) | XXX | (65%) | XXX | XXX | XXX |
| Net Profit | ($1M) | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | (60%) | XXX | (67%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Genetic Analysis Stock Performance
Genetic Analysis has current market cap of $5M, and enterprise value of $4M.
Market Cap Evolution
Genetic Analysis' stock price is $0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $5M | 0.6% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGenetic Analysis Valuation Multiples
Genetic Analysis trades at 2.0x EV/Revenue multiple, and (6.6x) EV/EBITDA.
EV / Revenue (LTM)
Genetic Analysis Financial Valuation Multiples
As of April 8, 2026, Genetic Analysis has market cap of $5M and EV of $4M.
Equity research analysts estimate Genetic Analysis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genetic Analysis has a P/E ratio of (4.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5M | XXX | $5M | XXX | XXX | XXX |
| EV (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | (6.6x) | XXX | (6.6x) | XXX | XXX | XXX |
| EV/EBIT | (3.4x) | XXX | (3.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | 3.1x | XXX | XXX | XXX |
| P/E | (4.4x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (12.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Genetic Analysis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Genetic Analysis Margins & Growth Rates
Genetic Analysis' revenue in the last 12 month grew by 36%.
Genetic Analysis' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Genetic Analysis' rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genetic Analysis' rule of X is 74% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Genetic Analysis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | (31%) | XXX | (34%) | XXX | XXX | XXX |
| EBITDA Growth | (48%) | XXX | (22%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 136% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Genetic Analysis Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Prostatype Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| Brainscan | XXX | XXX | XXX | XXX | XXX | XXX |
| Elite Diagnostic | XXX | XXX | XXX | XXX | XXX | XXX |
| Spermosens | XXX | XXX | XXX | XXX | XXX | XXX |
| Level Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genetic Analysis M&A Activity
Genetic Analysis acquired XXX companies to date.
Last acquisition by Genetic Analysis was on XXXXXXXX, XXXXX. Genetic Analysis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Genetic Analysis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGenetic Analysis Investment Activity
Genetic Analysis invested in XXX companies to date.
Genetic Analysis made its latest investment on XXXXXXXX, XXXXX. Genetic Analysis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Genetic Analysis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Genetic Analysis
| When was Genetic Analysis founded? | Genetic Analysis was founded in 2008. |
| Where is Genetic Analysis headquartered? | Genetic Analysis is headquartered in Norway. |
| How many employees does Genetic Analysis have? | As of today, Genetic Analysis has over 16 employees. |
| Is Genetic Analysis publicly listed? | Yes, Genetic Analysis is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Genetic Analysis? | Genetic Analysis trades under GEAN ticker. |
| When did Genetic Analysis go public? | Genetic Analysis went public in 2021. |
| Who are competitors of Genetic Analysis? | Genetic Analysis main competitors are Prostatype Genomics, Brainscan, Elite Diagnostic, Spermosens. |
| What is the current market cap of Genetic Analysis? | Genetic Analysis' current market cap is $5M. |
| What is the current revenue of Genetic Analysis? | Genetic Analysis' last 12 months revenue is $2M. |
| What is the current revenue growth of Genetic Analysis? | Genetic Analysis revenue growth (NTM/LTM) is 36%. |
| What is the current EV/Revenue multiple of Genetic Analysis? | Current revenue multiple of Genetic Analysis is 2.0x. |
| Is Genetic Analysis profitable? | No, Genetic Analysis is not profitable. |
| What is the current EBITDA of Genetic Analysis? | Genetic Analysis has negative EBITDA and is not profitable. |
| What is Genetic Analysis' EBITDA margin? | Genetic Analysis' last 12 months EBITDA margin is (31%). |
| What is the current EV/EBITDA multiple of Genetic Analysis? | Current EBITDA multiple of Genetic Analysis is (6.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.